Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

A solid formulation comprising a compound of Formula (I):

• or a pharmaceutically acceptable salt, amorphous form or polymorph form thereof, in an amount from about 30 wt % to about 50 wt %, and one or more excipients, wherein the one or more excipients comprise diluents or fillers, a disintegrant, a lubricant and a binding agent.

A solid formulation comprising a compound of Formula (I):

• or a pharmaceutically acceptable salt, amorphous form or polymorph form thereof, in an amount from about 20 wt % to about 50 wt %, microcrystalline cellulose, croscarmellose sodium, and hydroxypropyl cellulose.

A solid formulation comprising a compound of Formula (I):

• or a pharmaceutically acceptable salt, amorphous form or polymorph form thereof, in an amount from about 20 wt % to about 50 wt %, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, mannitol and a lubricant.